why choose us

First received: August 01, 2023

Clinical Trial: Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Brief Summary: This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment or has not responded to previous treatment (refractory).Multiple myeloma (MM) remains the second most common hematologic malignancy in the United States.A number of therapies have been approved for patients with MM, including CD38- and B-cell…

Read more